Benzinga · Aug 12, 2026
Truist Securities Maintains Buy on Immunome, Raises Price Target to $38
Truist Securities analyst Supawat Thongthip maintains Immunome (NASDAQ:IMNM) with a Buy and raises the price target from $37 to $38.
IM
NASDAQ · IMNM
Immunome, Inc.
Healthcare · Biotechnology
$28.08
Up+$0.44 (+1.57%)
Updated Aug 21, 2026, 11:28 PM
SID Score
6.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.79B
- P/E ratio
- -7.98
- Dividend yield
- 0.00%
- 52-week range
- $17.83 – $30.06
- Volume
- 1.03M
- Avg. volume
- 1.51M
Price performance
IMNM price history
1M range · 0 trading sessions · Daily adjusted prices
IMNM does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest IMNM news
The latest Smart Investors Daily articles mentioning IMNM.
Stock researchCompany · Overview
IMNM research
Overview
Company profile and research snapshot.
Company profile
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $28.25
- Implied upside
- —
- Analysts
- 18
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2026 | Wedbush | Outperform | — |
| Aug 12, 2026 | Truist Securities | Buy | — |
| Jul 21, 2026 | Wedbush | Outperform | — |
| Jun 12, 2026 | Wedbush | Outperform | — |
| May 28, 2026 | Truist Securities | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 12, 2026
Wedbush Maintains Outperform on Immunome, Raises Price Target to $35
Wedbush analyst David Nierengarten maintains Immunome (NASDAQ:IMNM) with a Outperform and raises the price target from $31 to $35.
Benzinga · Aug 11, 2026
Immunome Q2 EPS $(0.65) Misses $(0.52) Estimate
Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.52) by 25 percent. This is a 30 percent decrease over losses of $(0.50) per share from the same
Benzinga · Jul 21, 2026
Wedbush Reiterates Outperform on Immunome, Maintains $31 Price Target
Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $31 price target.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
